<p>纽约市，纽约州 / ACCESS Newswire /2025 年 12 月 22 日/ Pomerantz LLP 宣布已对 Inspire Medical Systems, Inc.（&#34;Inspire&#34; 或 &#34;公司&#34;）提起集体诉讼。建议相关投资者联系 Danielle Peyton，电话 7980。通过电子邮件咨询的投资者请务必提供邮寄地址、电话号码以及购买的股票数量。</p>
<p>该集体诉讼涉及 Inspire 及其某些高管和/或董事是否参与了证券欺诈或其他非法商业行为。</p>
<p>如果您在集体诉讼期间购买或以其他方式获得了 Inspire 的证券，您有时间在 2026 年 1 月 5 日之前请求法院任命您为集体的首席原告。您可以在 <strong>www.pomerantzlaw.com</strong> 获取诉状副本。</p>
<p>[点击这里获取有关加入集体诉讼的信息]</p>
<p>2025 年 8 月 4 日，Inspire 披露，由于多项之前未披露的阻力，Inspire V（公司新款睡眠呼吸暂停设备）的推出面临 &#34;延长的时间框架&#34;。首先，&#34;许多中心未能完成购买和植入 Inspire V 前所需的培训、合同和入职标准。&#34; Inspire 还披露，尽管 Inspire V 的 CPT 代码已获得 Medicare 患者的批准，但 &#34;索赔提交和处理的软件更新直到 7 月 1 日才生效，&#34;这意味着 &#34;植入中心在 7 月 1 日之前无法为这些程序收费。&#34;因此，许多治疗中心选择继续使用 Inspire IV 设备进行治疗。最后，投资者首次了解到，过剩的库存也对 Inspire V 的推出产生了负面影响。由于上述问题，Inspire 将其盈利指引下调超过 80%，从每股 2.20 至 2.30 美元的范围降至仅每股 0.40 至 0.50 美元。</p>
<p>在这一消息发布后，Inspire 的股价在 2025 年 8 月 5 日下跌了 42.04 美元，跌幅超过 32%，收于每股 87.91 美元。</p>
<p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为企业、证券和反垄断集体诉讼领域的顶尖律师事务所之一。该事务所由已故的 Abraham L. Pomerantz 创立，他被誉为集体诉讼领域的权威，Pomerantz 开创了证券集体诉讼的领域。时至今日，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、信托责任违反和公司不当行为的受害者争取权利。该事务所已为集体成员追回了多项数百万美元的赔偿。请参见 www.pomlaw.com。</p>
<p>律师广告。以往的结果并不保证类似的结果。</p>
<p><strong>来源：</strong> Pomerantz LLP</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

启迪医疗

<p>Pomerantz LLP 已对 Inspire Medical Systems, Inc. 提起集体诉讼，指控其涉嫌证券欺诈。该诉讼是在 Inspire 公开其新款睡眠呼吸暂停设备 Inspire V 的推出因培训和软件问题而延迟后提起的，这导致其盈利预期大幅下调，股价下跌 32%。投资者有直到 2026 年 1 月 5 日的时间申请担任首席原告</p>

<p>NEW YORK CITY, NY / ACCESS Newswire / December 22, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (&#34;Inspire&#34; or the &#34;Company&#34;) . Such investors are advised to contact Danielle Peyton at 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.</p>
<div class="lb-trans"><p>纽约市，纽约州 / ACCESS Newswire /2025 年 12 月 22 日/ Pomerantz LLP 宣布已对 Inspire Medical Systems, Inc.（&#34;Inspire&#34; 或 &#34;公司&#34;）提起集体诉讼。建议相关投资者联系 Danielle Peyton，电话 7980。通过电子邮件咨询的投资者请务必提供邮寄地址、电话号码以及购买的股票数量。</p>
</div><p>The class action concerns whether Inspire and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.</p>
<div class="lb-trans"><p>该集体诉讼涉及 Inspire 及其某些高管和/或董事是否参与了证券欺诈或其他非法商业行为。</p>
</div><p>You have until January 5, 2026 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Inspire securities during the Class Period. A copy of the Complaint can be obtained at <strong>www.pomerantzlaw.com</strong> <strong>.</strong></p>
<div class="lb-trans"><p>如果您在集体诉讼期间购买或以其他方式获得了 Inspire 的证券，您有时间在 2026 年 1 月 5 日之前请求法院任命您为集体的首席原告。您可以在 <strong>www.pomerantzlaw.com</strong> 获取诉状副本。</p>
</div><p>[Click here for information about joining the class action]</p>
<div class="lb-trans"><p>[点击这里获取有关加入集体诉讼的信息]</p>
</div><p>On August 4, 2025, Inspire disclosed that the launch of Inspire V, the Company's new sleep apnea device, was facing an &#34;elongated timeframe&#34; due to a number of previously undisclosed headwinds. First, &#34;many centers did not complete the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V.&#34; Inspire also disclosed that, although Inspire V's CPT code had been approved for Medicare patients, &#34;software updates for claims submissions and processing did not take effect until July 1,&#34; which meant that &#34;implanting centers would not be able to bill for those procedures until July 1.&#34; As a result, many treatment centers simply chose to continue treating with the Inspire IV device until then. Finally, investors also learned for the first time that excess inventory was also negatively impacting the Inspire V rollout. As a result of the foregoing issues, Inspire reduced its earnings guidance by more than 80%, from a range of $2.20 to $2.30 per share to just $0.40 to $0.50 per share.</p>
<div class="lb-trans"><p>2025 年 8 月 4 日，Inspire 披露，由于多项之前未披露的阻力，Inspire V（公司新款睡眠呼吸暂停设备）的推出面临 &#34;延长的时间框架&#34;。首先，&#34;许多中心未能完成购买和植入 Inspire V 前所需的培训、合同和入职标准。&#34; Inspire 还披露，尽管 Inspire V 的 CPT 代码已获得 Medicare 患者的批准，但 &#34;索赔提交和处理的软件更新直到 7 月 1 日才生效，&#34;这意味着 &#34;植入中心在 7 月 1 日之前无法为这些程序收费。&#34;因此，许多治疗中心选择继续使用 Inspire IV 设备进行治疗。最后，投资者首次了解到，过剩的库存也对 Inspire V 的推出产生了负面影响。由于上述问题，Inspire 将其盈利指引下调超过 80%，从每股 2.20 至 2.30 美元的范围降至仅每股 0.40 至 0.50 美元。</p>
</div><p>On this news, Inspire's stock price fell $42.04 per share, or more than 32%, to close at $87.91 per share on August 5, 2025.</p>
<div class="lb-trans"><p>在这一消息发布后，Inspire 的股价在 2025 年 8 月 5 日下跌了 42.04 美元，跌幅超过 32%，收于每股 87.91 美元。</p>
</div><p>Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.</p>
<div class="lb-trans"><p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为企业、证券和反垄断集体诉讼领域的顶尖律师事务所之一。该事务所由已故的 Abraham L. Pomerantz 创立，他被誉为集体诉讼领域的权威，Pomerantz 开创了证券集体诉讼的领域。时至今日，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、信托责任违反和公司不当行为的受害者争取权利。该事务所已为集体成员追回了多项数百万美元的赔偿。请参见 www.pomlaw.com。</p>
</div><p>Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p>律师广告。以往的结果并不保证类似的结果。</p>
</div><p><strong>SOURCE:</strong> Pomerantz LLP</p>
<div class="lb-trans"><p><strong>来源：</strong> Pomerantz LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

Pomerantz LLP 提醒在启迪医疗系统公司（Inspire Medical Systems, Inc.）投资中遭受损失的投资者